Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Tyson Foods, Inc. (TSN) Price & Performance

Crispr Therapeutics AGTrade
Tyson Foods, Inc.Trade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Tyson Foods, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.83 (market cap $5.23B), while Tyson Foods, Inc. trades at $55.93 (market cap $19.85B). The key difference: Tyson Foods, Inc. is far larger — about 3.8× Crispr Therapeutics AG's market cap, and Tyson Foods, Inc. pays a 3.62% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

CRSPTSN
Market Cap
$5.23B$19.85B
Sector
HealthConsumer Staples
52-Week High
$76.78$68.75
52-Week Low
$44.34$50.72
Enterprise Value
$3.65B$27.12B
Dividend Yield
3.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.

Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.

Tyson Foods, Inc.

Tyson Foods (TSN) trades at $57.16, down 1.52% on the day, amid a bearish technical signal. The company reported mixed Q3 2026 earnings, beating EPS estimates but missing revenue expectations, with beef segment losses weighing on results. Analyst consensus is a Buy with a $68.50 price target, but technical indicators show selling pressure. Recent news highlights debt tender offers and a maintained dividend, while cash flow trends show volatility.

The outlook is cautious; strong chicken and prepared foods segments provide stability, but persistent beef losses and volume declines pose near-term risks. Valuation metrics like P/E of 34.83 appear elevated relative to modest profitability, yet the stock trades below analyst targets, suggesting potential upside if operational challenges ease.

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About Tyson Foods, Inc.

Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.

Read more on TSN